Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26307134.
- Also identified by DOI 10.1158/1078-0432.CCR-15-1613.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Notch signaling is implicated in prostate cancer progression and docetaxel resistance. Cui and colleagues describe the additive efficacy and mechanisms of a γ-secretase inhibitor, PF-03084014, and docetaxel in preclinical models of prostate cancer, suggesting the need for further clinical development of Notch pathway modulators in men with metastatic prostate cancer.
Medical subject headings
- Amyloid Precursor Protein Secretases
- Antineoplastic Combined Chemotherapy Protocols
- Prostatic Neoplasms